PMVP logo

PMV PHARMACEUTICALS INC

PMVPNASDAQ
🏆 #4232 by market capEarnings Nov 10US Equity
$742.68▼ $21.09 (−2.84%)
Simulated price
🔔
Track PMVP
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 2.8%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$76M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
56
Weak
No chart data available for PMVP.

Trading Snapshot

Day Range
$732.64 – $747.36
52-Week Range
$1.02 – $1.88
Volume
$2.73B
Avg Volume
$2.21B
Shares Outstanding
53.3M
Next Earnings
Nov 20, 2026

Fundamentals Snapshot

Annual Revenue
$11M
Last Q Revenue
$3M
P/E Ratio
-1.0
P/S Ratio
0.0x
EPS (TTM)
$-1.41
Dividend Yield
0.00%
Dilution (1yr)
+3.3%

Why Investors Own PMVP

  • ✓High-growth profile — revenue up +28.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 43% gross margin and 8% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PMVP logo

PMV PHARMACEUTICALS INC

PMVP
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$86M▲ +0.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$74M▲ +41.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
53.3M▲ +3.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$37M▼ −$3M YoY
StockOtter · stockotter.space

About PMV PHARMACEUTICALS INC

PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Price Target

ⓘ
Average Target
$726.48
▼ −2.2% Downside
High Target$849.53
Low Target$583.19
Based on 33 analysts

Latest News & Updates

🚀
Bloomberg·2h ago

PMV PHARMACEUTICALS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift PMVP price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

PMV PHARMACEUTICALS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.